乳腺癌 z-bo 2020-10-09 319

　　A new study led by Flinders University recently found a link between beta blockers and the survival outcomes of certain breast cancer patients.

　　According to a new paper by Frontiers In Oncology, β-blockers commonly used to treat cardiovascular diseases are negatively correlated with the survival outcomes of patients with HER2-positive advanced breast cancer (human epidermal growth factor receptor 2). Have. Using data collected from clinical trials conducted in 2777 patients, the study performed the HER2-positive ABC group with β-blockers compared to patients who did not use β-blockers. The result is poor, indicating the survival of the patient.

　　Professor Michael Sorich (Michael Sorich) of Flinders University School of Medicine and School of Public Health Precision Medicine said: "This study emphasizes that the survival outcome of this group of breast cancer patients is very poor."

　　"About 20% of breast cancer patients overexpress HER2 and anti-HER2 therapy with known cardiovascular toxicity. Given that this is a complex treatment, this study has identified an important subgroup of patients. It is recommended that further studies be conducted to seek improvement . Strategies for treatment outcomes. I concluded. “Future research should aim to better understand specific breast cancer subtypes, cancer types, and the impact of β-blockers on cancer treatment. "